Amjad Husain, MD
Internal Medicine · Nashua, NHNPI 1952391849
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $870 of the $970 with a category attached, or 89.6%. 12 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 42.5% of the total. 2025 is the largest year on record at $730, more than ten times the $16 reported in 2019. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $34.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$412
- GSK$112
- AstraZeneca$110
- Pfizer$75
- Sanofi$66
- Regeneron Healthcare Solutions, Inc.$40
- plus $153 from 6 others
What the payments were for
- Food & beverage$87090%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 6 | $412 |
| GSK | 6 | $112 |
| AstraZeneca | 5 | $110 |
| Pfizer | 1 | $75 |
| Sanofi | 2 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Boehringer Ingelheim | 1 | $32 |
| United Therapeutics Corporation | 1 | $25 |
| Insmed, Inc. | 1 | $25 |
| Amgen | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$283
How this compares
$970 in reported general payments places this provider in the 90th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 467 | $449,342 |
| Breo ElliptaFluticasone/Vilanterol | 214 | $133,073 |
| XolairOmalizumab | 34 | $133,034 |
| Spiriva RespimatTiotropium Bromide | 79 | $62,998 |
| Advair HfaFluticasone Propion/Salmeterol | 72 | $42,057 |
| SymbicortBudesonide/Formoterol Fumarate | 98 | $36,897 |
| EliquisApixaban | 42 | $31,793 |
| Incruse ElliptaUmeclidinium Bromide | 56 | $29,252 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $23,754 |
| Arnuity ElliptaFluticasone Furoate | 57 | $19,537 |
| BreynaBudesonide/Formoterol Fumarate | 45 | $14,896 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 533 | $14,127 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $13,880 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $12,858 |
| DuleraMometasone/Formoterol | 31 | $12,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $112 | $640,879809 claims |
| Boehringer IngelheimSpiriva Respimat | $32 | $62,99879 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $110 | $60,651128 claims |
| PfizerEliquis | $75 | $31,79342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Nashua
- Kevin PhoNashua$40K
- Yair MelamedNashua$3K
- Shaji HabeebullaNashua$3K
- Maxim SmirnovNashua$2K
- Suneetha KammilaNashua$1K
- Win KyawNashua$640
- Donald RainoneLondonderry$1.9M
- Brian HyettPortsmouth$185K
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.